MAPT and Alzheimer disease: However, recent studies based on in vitro binding assays indicate that those various tracers demonstrate preferential binding capability to distinctive tau pathologies observed in AD and non-AD, suggesting each tracer potentially recognizes the different structural status of tau aggregates (Maruyama et al., 2013; Marquie et al., 2015).